GlassScriptPhysician profile
Robert J Fischer
NPI 1023378759
$10,682.13
in general payments reported to CMS, 2019-2025
35 companies · $3,188 in 2025
The $3,188 reported for 2025 was more than what 92% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $776 · 2021: $1,590 · 2022: $1,194 · 2023: $1,213 · 2024: $1,455 · 2025: $3,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,858 · Travel and Lodging: $1,714 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,857.87 |
| Travel and Lodging | $1,713.77 |
| Education | $284.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,316.30 | 2019-2025 | |
| Kerecis Limited | $1,713.77 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Regeneron Healthcare Solutions, INC. | $828.95 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $698.64 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $649.59 | 2019-2025 | |
| Amgen INC. | $565.18 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $477.87 | 2019-2024 | Winlevi |
| Ucb, INC. | $461.94 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $412.39 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $275.06 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $263.63 | 2019-2024 | Siliq |
| Dermavant Sciences, INC. | $218.79 | 2022-2024 | Vtama |
| Organogenesis INC. | $211.23 | 2023-2024 | Puraply, Apligraf |
| Vyne Pharmaceuticals INC. | $201.95 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $201.82 | 2019-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $178.79 | 2019-2023 | |
| Pfizer INC. | $178.57 | 2019-2021 | |
| Genzyme Corporation | $145.98 | 2020-2025 | |
| Incyte Corporation | $109.35 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $104.98 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $95.99 | 2019-2020 | |
| Dermira, INC. | $75.62 | 2019-2021 | |
| Almirall LLC | $50.19 | 2020-2022 | |
| Strata Skin Sciences, INC. | $47.13 | 2020-2025 | Xtrac |
| Organon LLC | $26.23 | 2025 | Vtama |
| Celltrion USA INC. | $23.57 | 2023 | Yuflyma |
| Mylan Pharmaceuticals INC. | $21.56 | 2019 | |
| Celgene Corporation | $19.65 | 2019 | |
| Sebela Pharmaceuticals INC. | $18.14 | 2020 | |
| Sandoz INC. | $16.53 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $15.84 | 2022 | |
| Aclaris Therapeutics, INC. | $15.82 | 2019 | |
| Conmed Corporation | $15.44 | 2025 | Visiclear |
| Promius Pharma LLC | $14.56 | 2019 | |
| Allergan, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.